170 related articles for article (PubMed ID: 23106270)
41. In reply.
Takiff H; Alame-Emane AK; Pierre-Audigier C; Gicquel B
Int J Tuberc Lung Dis; 2016 Feb; 20(2):282-3. PubMed ID: 26792487
[No Abstract] [Full Text] [Related]
42. A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers.
Schito M; Dolinger DL
EBioMedicine; 2015 Oct; 2(10):1262-5. PubMed ID: 26629499
[No Abstract] [Full Text] [Related]
43. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?
Yew WW; Koh WJ
Korean J Intern Med; 2016 Jan; 31(1):15-29. PubMed ID: 26767853
[TBL] [Abstract][Full Text] [Related]
44. Editorial commentary: pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance.
Egelund EF; Peloquin CA
Clin Infect Dis; 2012 Jul; 55(2):178-9. PubMed ID: 22467672
[No Abstract] [Full Text] [Related]
45. Efficacy and safety of regimens for drug-resistant tuberculosis.
Yates TA; Nunn AJ
Lancet Infect Dis; 2016 Nov; 16(11):1218-1219. PubMed ID: 27788973
[No Abstract] [Full Text] [Related]
46. BPaL approved for multidrug-resistant tuberculosis.
Burki T
Lancet Infect Dis; 2019 Oct; 19(10):1063-1064. PubMed ID: 31559963
[No Abstract] [Full Text] [Related]
47. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM;
Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911
[No Abstract] [Full Text] [Related]
48. Pakistan's battle with multi-drug resistant tuberculosis--establishing the ground rules.
Saleem T; Khalid U
J Pak Med Assoc; 2012 Jan; 62(1):80. PubMed ID: 22352115
[No Abstract] [Full Text] [Related]
49. WHO strategies for the management of drug-resistant tuberculosis.
Rendon A; Centis R; D'Ambrosio L; Migliori GB
Arch Bronconeumol; 2017 Mar; 53(3):95-97. PubMed ID: 27717622
[No Abstract] [Full Text] [Related]
50. Mechanisms of drug resistance in Mycobacterium tuberculosis.
Zhang Y; Yew WW
Int J Tuberc Lung Dis; 2009 Nov; 13(11):1320-30. PubMed ID: 19861002
[TBL] [Abstract][Full Text] [Related]
51. Analysis of Green Light Committee implementation and acquisition of second-line drug resistance.
Metcalfe JZ; Vittinghoff E; Hopewell PC
Clin Infect Dis; 2015 Mar; 60(6):970. PubMed ID: 25527651
[No Abstract] [Full Text] [Related]
52. [Primary drug resistance of Mycobacterium tuberculosis in patients with new-onset destructive pulmonary tuberculosis].
Zinov'ev IP; Esaulova NA; Novikov VG; Kokovikhina IA
Probl Tuberk Bolezn Legk; 2009; (4):37-9. PubMed ID: 19514452
[TBL] [Abstract][Full Text] [Related]
53. Drug-resistance--a challenge for tuberculosis control in the European Union and European Economic Area.
van der Werf MJ; Sprenger M
Euro Surveill; 2014 Mar; 19(11):. PubMed ID: 24679718
[No Abstract] [Full Text] [Related]
54. How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?
Gebhard A; van den Hof S; Cobelens F
Am J Respir Crit Care Med; 2015 Jul; 192(1):117. PubMed ID: 26131997
[No Abstract] [Full Text] [Related]
55. No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
Cobelens F; Gebhard A; van den Hof S
Int J Tuberc Lung Dis; 2016 Feb; 20(2):282. PubMed ID: 26792486
[No Abstract] [Full Text] [Related]
56. [Spread of multidrug resistance of Mycobacterium and its impact on the efficiency of treatment in patients with tuberculosis in the penitentiaries of the Arkhangelsk Region].
Mar'iandyshev AO; Nizovtseva NI; Glomozda PG; Panasik VP; Duginova TN; Kuznetsov AA
Probl Tuberk Bolezn Legk; 2005; (5):19-21. PubMed ID: 15988972
[TBL] [Abstract][Full Text] [Related]
57. Reply: How Do the New Definitions for Multidrug-Resistant Tuberculosis Treatment Outcomes Really Perform?
Bastard M; Bonnet M; du Cros P; Khamraev AK; Hayrapetyan A; Kimenye K; Khurkhumal S; Dlamini T; Telnov A; Sanchez-Padilla E; Hewison C; Varaine F
Am J Respir Crit Care Med; 2015 Jul; 192(1):117-8. PubMed ID: 26131996
[No Abstract] [Full Text] [Related]
58. [Clofazimine in treatment of multi-drug resistant tuberculosis].
Jing W; Wang QF; Chu NH
Zhonghua Jie He He Hu Xi Za Zhi; 2016 May; 39(5):396-9. PubMed ID: 27180598
[No Abstract] [Full Text] [Related]
59. Resistant plus susceptible tuberculosis: the undiscovered country.
Ahmad Khan F; Behr M
J Infect Dis; 2014 Jun; 209(11):1682-4. PubMed ID: 24523512
[No Abstract] [Full Text] [Related]
60. Microscopic observation drug susceptibility (MODS): where are we going?
Kam KM
Int J Tuberc Lung Dis; 2014 Feb; 18(2):127. PubMed ID: 24429301
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
